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Abstract To determine if NMDA receptor alterations are
present in the cerebellum in schizophrenia, we measured
NMDA receptor binding and gene expression of the NMDA
receptor subunits in a post-mortem study of elderly patients
with schizophrenia and non-affected subjects. Furthermore,
we assessed inﬂuence of genetic variation in the candidate
gene neuregulin-1 (NRG1) on the expression of the NMDA
receptor in an exploratory study. Post-mortem samples from
the cerebellar cortex of ten schizophrenic patients were
compared with nine normal subjects. We investigated
NMDA receptor binding by receptor autoradiography and
gene expression of the NMDA receptor subunits NR1,
NR2A, NR2B, NR2C and NR2D by in situ hybridization.
For the genetic study, we genotyped the NRG1 polymor-
phism rs35753505 (SNP8NRG221533). Additionally, we
treated rats with the antipsychotics haloperidol or clozapine
and assessed cerebellar NMDA receptor binding and gene
expression of subunits to examine the effects of antipsy-
chotic treatment. Gene expression of the NR2D subunit was
increased in the right cerebellum of schizophrenic patients
compared to controls. Individuals carrying at least one C
allele of rs35753505 (SNP8NRG221533) showed decreased
expression of the NR2C subunit in the right cerebellum,
compared to individuals homozygous for the T allele.
Correlation with medication parameters and the animal
model revealed no treatment effects. In conclusion,
increased NR2D expression results in a hyperexcitable
NMDA receptor suggesting an adaptive effect due to
receptor hypofunction. The decreased NR2C expression in
NRG1 risk variant may cause a deﬁcit in NMDA receptor
function. This supports the hypothesis of an abnormal
glutamatergic neurotransmission in the right cerebellum in
the pathophysiology of schizophrenia.
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Introduction
The cerebellum is known to be involved in motor control,
but positron emission tomography (PET) and functional
magnetic resonance imaging (fMRI) studies have also
shown the involvement of the cerebellum in different
cognitive tasks [2, 51]. During the last decades, the cere-
bellum has been implicated in the pathophysiology of
schizophrenia, with the cortico-thalamo-cerebellar circuit
receiving particular attention [4]. Evidence from PET as
well as structural and functional MRI studies has shown
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hemisphere and right vermis [60] as well as correlation of
the volume reduction with psychopathological subscores
[26, 43]. This has raised questions concerning the under-
lying biological dysfunction.
1H-spectroscopic MRI studies
have revealed decreased N-acetylaspartate (NAA) and
creatine in the anterior vermis and cortex, pointing to
altered neuronal integrity [12, 17]. Reductions of NAA
indicate a loss of functional and structural integrity of
neurons, dendrites and axons. Such neuronal dysfunctions
may involve a glutamatergic deﬁcit in cerebellar subre-
gions of schizophrenic patients.
The glutamate hypothesis of schizophrenia is based on
the observation that phencyclidine and ketamine, which
block the ion channel of the glutamatergic N-methyl-D-
aspartate (NMDA) receptor, initiate an NMDA receptor
hypofunction and precipitate psychosis [29, 30], resulting
in a ﬁnal hypoglutamatergic state of corticostriatal pro-
jections [18, 44]. The NMDA receptor is composed of
different subunits, responsible for various functional
properties [27, 39]. The obligate NR1 subunit combines
two or three NR2 subunits (NR2A, NR2B, NR2C and
NR2D) to form the functional receptor.
Studies, using brain tissue obtained from post-mortem,
have examined the expression of glutamate receptor sub-
units and support the hypothesis of a glutamate dysfunction
in schizophrenia. In contrast to neocortical brain regions,
molecular investigations of the cerebellum are sparse
concerning schizophrenia. In cerebellar Purkinje and Golgi
neurons, all NMDA receptor subunits are expressed [10,
52] and may be altered in schizophrenia. However, one
study investigating only the left cerebellar granule cell
layer showed no difference in gene expression of NMDA
receptor subunits compared to healthy controls [1]. The
expression of the NR2C subunit has been reported to be
regulated by neuregulin-1 in maturing synapses of the
cerebellar granule cells [47]. Several studies suggest NRG1
as a vulnerability gene for schizophrenia [23]. The mech-
anisms that might underlie the contribution of NRG1 risk
haplotypes to disease pathophysiology, however, remain
elusive. Particularly, the inﬂuence of NRG1 risk variants on
the expression of subunits of the NMDA receptor is
unknown.
The present study sought to determine whether the
expression of genes encoding for NR1, NR2A, NR2B,
NR2C and NR2D subunits of the NMDA receptor or
NMDA receptor binding are speciﬁcally altered in the
cerebellum. For additional investigation of a possible
inﬂuence of NRG1 genotype variation on the expression of
the NR2C subunit, we genotyped the samples for the NRG1
polymorphism rs35753505 (SNP8NRG221533). This
variant forms part of the previously reported risk haplotype
for schizophrenia, and has been described as a tagging SNP
of the core at-risk haplotype [23]. As all schizophrenic
patients in our study had been on antipsychotic medication
over long periods of time, medication effects have to be
included as a possible inﬂuential factor. Accordingly, we
conducted an additional animal study closely investigating
the effects of a typical (haloperidol) and an atypical
(clozapine) antipsychotic medication on NMDA receptor
binding and gene expression of subunits of the NMDA
receptor in different cerebellar rat brain regions after drug
administration for up to 6 months.
Method
Human post-mortem tissue
Frozen post-mortem brain samples from inpatients with
DSM-IV residual schizophrenia (n = 10) and elderly
comparison subjects (n = 9) were collected at the Central
Institute of Mental Health, Mannheim and the Department
of Neuropathology, Wiesloch, Germany. The sex distri-
bution, mean age, age at onset, duration of the disease,
duration of hospitalization, last dose and cumulative dose
during the last 10 years of antipsychotic medication in
chlorpromazine equivalents (CPE), post-mortem interval
(PMI), brain pH and storage time interval are shown in
Table 1. Complete medical charts were available for all
patients.
All schizophrenic patients had been long-term inpatients
at the State Mental Hospital in Wiesloch, Germany.
Patients were diagnosed ante mortem by an experienced
psychiatrist, who also conducted diagnostic reviews of all
medical charts. For each patient the history of antipsy-
chotic treatment was assessed by examining the medical
charts. Subject’s last dose as well as the cumulative dose
during the last 10 years of antipsychotic medication was
calculated in chlorpromazine equivalents (CPE) through
the algorithm developed by Jahn and Mussgay [28].
Autopsy consent was obtained from the donor or a family
member in all cases. The Ethics Committee of the Faculty
of Medicine of Heidelberg University, Germany, approved
all assessments and post-mortem evaluations and
procedures.
All patients and controls had undergone thorough
neuropathologic characterization to rule out associated
neurovascular or neurodegenerative disorders such as
Alzheimer’s disease and multi-infarct dementia [7, 8]. The
staging according to Braak was 2 or less for all subjects.
Patients and normal comparison subjects had no history of
alcohol or drug abuse, or severe physical illness (like
carcinoma). Normal comparison subjects had no history of
psychiatric disorders. All patients had been receiving long-
term antipsychotic medication before dying such as
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123clozapine (n = 3), zotepine (n = 1), olanzapine (n = 2),
ﬂupenthixole (n = 1), haloperidol (n = 3), perphenazine
(n = 1), pipamperone (n = 1), promethazine (n = 1), tia-
pride (n = 1) and zuclopenthixol (n = 2).
The cerebellum was dissected in the midline of the
vermis. Tissue blocks were prepared from cerebellar sub-
regions, the anterior lateral hemisphere and anterior vermis
from both hemispheres of the cerebellum. Blocks were
immediately snap-frozen in liquid nitrogen-cooled isopen-
tane, and stored at -80C.
NRG1 rs35753505 (SNP8NRG221533), genotyping
and use of online bioinformatics tools
Sequence information for NRG1 was obtained from the
homepage of deCODE Genetics (http://decode.com/nrg1/
markers/SNPS.htm). SNP rs35753505 (SNP8NRG221533)
was genotyped using Applied Biosystems 7900HT Fast
Real-Time PCR System and TaqMan-probes designed by
Applied Biosystems (Foster City, California). Primers and
VIC/FAM-probe sequences for rs35753505 (SNP8NR
G221533) detection were: forward-50-TTTAAGGCATCA
GTTTTCAATAGCTTTTTTATGT-30; Reverse-50-AGAC
AGATGTCTCAAGAGACTGGAA-30;5 0-VIC-CATGTA
TCTTTATTTTGCCAAAT-30;5 0-FAM-CATGTATCTTT
ATTTTACCAAAT.
To test for functional constraint on the genomic region,
in which rs35753505 (SNP8NRG221533) is located, cross-
species conservation analysis was carried out using the
ECR browser (http://ecrbrowser.dcode.org). The ECR
browser lists human SNPs which are located in evolu-
tionary conserved regions (ECRs). ECRs are DNA regions
that have been mapped to align with other genomes and are
conserved with greater than or equal to 70% identity over
at least 100 bp [38, 45]. For ECR browser analysis, gen-
ome assemblies hg18 (human), mm8 (mouse) and rn4 (rat)
were used (ECR browser, February 2007).
Animal model of antipsychotic treatment
Animal use procedures were in strict accordance with the
NIH guide for the Care and Use of Laboratory Animals and
had been approved by the local animal ethical care com-
mittee. Male Sprague-Dawley rats (initial weight 250–
280 g, Janvier, France) were group housed 3 per cage
under a 12-h light–dark cycle and fed ad libitum. Over a
period of 6 months, 11 rats received either haloperidol
(Janssen) at 1.5 mg/kg/day diluted in minimal acetic acid,
clozapine (Novartis) at 45 mg/kg/day diluted in minimal
HCl in the drinking water adjusted to pH 6.5. Control rats
were given minimal HCl in the drinking water to match the
pH levels of the drug solutions as described before [54, 64].
After 6 months of continuous drug administration, rats
were killed by CO2. All brains were removed and frozen in
liquid isopentane before being stored at -80C for
approximately 4 months.
Human and animal brain processing
Adjacent coronal cryostat sections of rat and human brain
tissues were processed at -20C and were thaw-mounted
on superfrost plus microscopic slides, dried and stored as
described earlier [54, 64]. Grey matter of the human cer-
ebellar regions was delineated into the molecular and
granular layer [21]. For NMDA receptor binding we did
not investigate the molecular and granular layer separately
due to lacking optical delineation of the two layers on
tritium-sensitive ﬁlms. Rat cerebellum regions were
delineated into the left and right anterior hemispheres, total
anterior vermis and a region containing all cerebellar nuclei
according to the rat brain atlas of Paxinos and Watson [48].
Table 1 Characteristics of post-mortem brain tissue from patients
with schizophrenia and normal comparison subjects
Characteristic Tissue from
patients with
schizophrenia
(n = 10)
Tissue from
normal
comparison
subjects
(n = 9)
Mean SD Mean SD
Subject’s gender (N)
Male 4 3
Female 6 6
Neuregulin-1 genotype (N)
TT 4 4
CT/CC 6 4 (1 not
determined)
Age at death (years) 63.70 12.21 64.56 14.51
Post-mortem interval (h) 17.10 8.77 27.33 26.74
pH 6.55 0.33 6.63 0.37
Storage time interval (months) 27.82 10.76 24.59 8.29
Age at onset (years) 24.60 7.36
Duration of the disease (years) 39.10 11.77
Duration of hospitalization (years) 25.10 15.32
Duration of antipsychotic
medication
(years)
35.00 9.72
Last dose of antipsychotic
medication
in chlorpromazine equivalents
(CPE in gram)
436.90 452.10
Cumulative dose (last ten years)
of antipsychotic medication in
chlorpromazine equivalents
(CPE in kilogram)
3.59 3.04
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123NMDA receptor autoradiography in human and animal
brain tissue
Using quantitative in vitro receptor autoradiography,
binding to N-methyl-D-aspartate (NMDA) receptor was
performed utilizing speciﬁc ligands according to the
method by Zilles et al. [63]. Binding assays were per-
formed in the presence of 30 lM glycine and 50 lM
spermidine with 5 nM [
3H]-MK-801 (dizocilpine maleate)
at 22C for 60 min. In adjacent sections, non-speciﬁc
binding was determined by adding MK-801 in 20,000-fold
excess [10
-4 m( ?) MK-801] into the incubation solution.
Non-speciﬁc binding was subtracted from total binding to
obtain speciﬁc binding.
[
3H]-sensitive ﬁlm (Hyperﬁlm, Amersham) was exposed
to Tritium-labelled sections for 4 weeks. Autoradiograms
were digitized using an image analysis system (Inter Active
Systems, Interfocus Germany). The grey value images of
the co-exposed plastic C
14 standards were used to compute
a calibration curve by non-linear, least-squares ﬁtting,
which deﬁned the relationship between grey values and
concentration of radioactivity. The plastic standards were
calibrated to tissue standards prepared from homogenized
brain tissue with known protein content in order to express
binding site densities on fmol/mg protein as described
earlier [54, 64].
In situ hybridization
The expression of NMDA receptor subunits was evaluated
by semiquantitative in situ-hybridization using speciﬁc
human and rat probes as listed in Table 2. Using subcloned
cDNA fragments as templates, we produced radioactively
labelled cRNA probes by in vitro transcription as described
earlier [38, 54]. Hybridization with antisense probes
(10
7 cpm/ml) was carried out at 55C under high strin-
gency conditions [50% formamide (Sigma)] and speciﬁcity
was veriﬁed by the inclusion of sense probes. After RNAse
A digest and dehydration, X-ray ﬁlms (Biomax MR1) were
exposed to slices for 2–6 days. Results were quantiﬁed
using the analysis image system (see also NMDA receptor
binding).
Materials and medication
[
3H]-MK-801 was obtained from NEN (Life Science
Products, Germany). Unlabelled MK-801 was purchased
from Sigma (Taufkirchen, Germany). Haloperidol (Janssen
Research Foundation) and clozapine (Novartis, Basel,
Switzerland) were provided by the respective companies.
All other chemicals were purchased from Sigma Chemicals
(Taufkirchen, Germany).
Statistical analysis
Statistical analyses were performed with SPSS11 [42]. All
tests were two-tailed. The level of signiﬁcance was deﬁned
as P\0.05. Results are presented as mean ± standard
deviation.
Post-mortem human data
Distributions for all dependent variables were examined in
the two groups using histograms and the Kolmogorov–
Smirnov test on normality [35]. Though the power for the
Kolmogorov–Smirnov test was not very high due to the
small sample size, the results nevertheless suggest a normal
distribution of the data and analysis by parametric tests.
Stepwise linear regression analyses (Pin = 0.05, Pout =
0.10) with the independent variables gender, age and PMI
were performed for all dependent variables. Analyses of
covariance (ANCOVA) were conducted to test for diag-
nostic group differences. The intervening factor gender and
covariates age, PMI, storage time and brain pH were added
to our analyses, if they showed signiﬁcant inﬂuence in the
initial regression analysis. Since NMDA receptor subunits
Table 2 Primer fragments used
in in situ-hybridization
assessing gene expression of N-
methyl-D-aspartic acid (NMDA)
receptor (NR) subunits in post-
mortem brain specimens from
human subjects and rats
Gene GenBank Accession
number
Fragment–position Fragment-size
(base-pairs)
Rat NR1-3a U_08266.1 2,472–2,996 525
Rat NR2A M_91561.1 4,035–4,585 551
Rat NR2B NM_008171 4,030–4,444 415
Rat NR2C NM_012575.2 1,876–2,420 544
Rat NR2D NM_022797.1 2,896–3,413 518
Human NR1 NM_000832 2,134–2,835 701
Human NR2A NM_000833 3,759–4,268 509
Human NR 2B XM_006636 4,183–4,604 415
Human NR 2C NM_000835 2,494–2,783 290
Human NR 2D U_000836 2,042–2,546 504
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different experiments, differences between diagnostic
groups were assessed with independent tests for signiﬁ-
cance. For additional investigation of the inﬂuence of
NRG1 genotype on the expression of the NR2C subunit,
ANOVA with factor NRG1 genotype (CT/CC vs. TT) was
calculated. Correlations between variables were performed
using Pearson product moment correlation coefﬁcients.
Data from animal model
The Kolmogorov–Smirnov test on normality was applied.
Since there were signiﬁcant deviations from the normal
distribution assumption, comparisons between the three
groups were analysed by Kruskal–Wallis tests and subse-
quently by two-tailed Wilcoxon Mann Whitney U tests.
Results
Gene expression of NMDA receptor subunits in the left and
right anterior hemisphere, vermis, granular and molecular
layers of the cerebellum for schizophrenic patients and
healthy controls is shown in Fig. 1. Expression of the NR2D
subunit in all right-side cerebellar regions was signiﬁcantly
higher in the schizophrenia group compared with our group
of normal elderly controls (vermis: molecular layer
F = 13.26;df = 1,14;P = 0.003,granularlayerF = 6.43;
df = 1, 14; P = 0.024; hemisphere: molecular layer
F = 6.13; df = 1, 17; P = 0.024, granular layer F = 4.92;
df = 1, 17; P = 0.04). We found no difference in the left
hemisphere and vermis. NR1, NR2A, NR2B and NR2C
subunits did not differ signiﬁcantly. Additionally, NMDA
receptor binding revealed no difference in any cerebellar
region between schizophrenic patients and healthy controls.
In both schizophrenic patients and normal comparison
subjects the NRG1 rs35753505 (SNP8NRG221533)
schizophrenia-riskgenotypescontainingatleastoneCallele
(CC and CT) decreased gene expression of the NR2C sub-
unit in the molecular layer of the right vermis (F = 5.2;
df = 1, 15; P = 0.037) and hemisphere (F = 4.9; df = 1,
16;P = 0.041)comparedtotheTTgenotype(Fig. 2).Inthe
left side, we found no genotype-speciﬁc differences.
SNP rs35753505 (SNP8NRG221533) is localized
upstream of all transcript isoforms (RefSeq) of neuregulin
1, as shown in Fig. 3. ECR browser analysis (ECR browser,
Feb. 2007) revealed that rs35753505 (SNP8NRG221533) is
listed among human SNPs which are located in ECRs
(greater than or equal to 70% identity over at least 100 bp,
human–mouse comparison). ECR browser ‘Grab ECR’
alignment from both species in pairwise comparisons
(Fig. 4a, b) showed the base position of rs35753505
(SNP8NRG221533) localized in a long conserved
homologous stretch (human/mouse, 400 bps, 74.8% iden-
tity, hg18 chr8:31593526-31593925; human/rat, 295 bps,
73.6% identity, hg18 chr8:31593526-31593820), which
suggests selection on the genomic region harbouring the
polymorphism. The location of the ECR relative to
rs35753505 (SNP8NRG221533) and neuregulin 1transcript
isoforms (RefSeq) is shown in Fig. 3.
Patients did not differ regarding age (F = 0.0; df = 1,
17; P = 0.89), PMI (F = 1.3; df = 1, 17; P = 0.27) and
gender (v
2 = 0.1; df = 1; P = 0.76) compared to the
normal elder group (Table 1). Regression analysis
revealed a signiﬁcant inﬂuence of gender (increased in
males vs. females, F = 6.2; df = 1, 16; P = 0.025) and
age (r =- 0.57; df = 15; P = 0.018) on the expression
of NR2D subunit in the molecular layer of the left
hemisphere or vermis, respectively. In the left granular
layer, age had an inﬂuence on NR2A subunit (r = 0.46;
df = 17; P = 0.048) in the hemisphere and PMI on the
expression of NR1 subunits (r =- 0.49; df = 16;
P = 0.039) in the vermis. Therefore, these variables were
entered to the main analyses as covariates. Duration of
illness correlated positively with gene expression of the
NR2C subunit in the molecular layer of the right hemi-
sphere (r = 0.70; df = 8; P = 0.02) and right vermis
(r = 0.71; df = 7; P = 0.03) as well as bilaterally in the
granular layer of the hemispheres (right: r = 0.69, df = 8,
P = 0.03; left: r = 0.65, df = 8, P = 0.04) and vermis
(right: r = 0.77, df = 7, P = 0.02; left: r = 0.75, df = 7,
P = 0.02). Additionally, duration of illness correlated
negatively with gene expression of the NR2D subunit in
the molecular layer (r =- 0.71; df = 7; P = 0.03) and in
the granular layer (r =- 0.78; df = 7; P = 0.01) of the
left vermis.
All schizophrenic patients had been exposed to anti-
psychotic medication for decades (Table 1). Furthermore,
patients had been receiving antipsychotic medication to
within 1 week of death. Duration of medication correlated
with expression of the NR2C subunit in the molecular layer
of the right hemisphere (r = 0.66; df = 8; P = 0.04) and
vermis (r = 0.69; df = 7; P = 0.04). In the molecular
layer of the left vermis, duration of medication correlated
negatively with expression of the NR2D subunit (r =
-0.73; df = 7; P = 0.03). In the granular layer of the
vermis, duration of medication correlated with expression
of the NR2C subunit (right: r = 0.82, df = 7, P = 0.01;
left: r = 0.75, df = 7, P = 0.03) and negatively with
expression of the NR2D subunit (left: r =- 0.79; df = 7;
P = 0.01). There was no correlation between gene
expression of NMDA receptor subunits and last dose or
cumulative dose in CPE.
In the animal model of long-term antipsychotic treat-
ment, Kruskal–Wallis test revealed a signiﬁcant group
effect of NR2C gene expression (v
2 = 7.0; df = 2;
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Fig. 1 Gene expression of N-methyl-D-aspartate (NMDA) receptor
subunits NR1, NR2A, NR2B, NR2C and NR2D expressed as Bq/g
brain tissue in the molecular layer (stratum moleculare: Sm) and
granular layer (stratum granulare: Sg) of the right and left vermis and
hemispheres. NMDA receptor binding expressed as pmol/mg protein
in the right and left vermis and hemispheres.
a,bSigniﬁcantly different
from comparison group
aP\0.05,
bP\0.01)
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123P = 0.030). As shown by a subsequent Mann–Whitney U
test expression of NR2C was increased in clozapine treated
animals compared to haloperidol treatment (Z =- 2.5;
df = 1; P = 0.038). There was no signiﬁcant difference in
the gene expression of NR1, NR2A, NR2B, NR2C and
NR2D subunits or NMDA receptor binding between saline-
treated rats and groups receiving clozapine or haloperidol
treatment.
Discussion
The present post-mortem studies revealed overexpression
of the NR2D subunit of the NMDA receptor in the
molecular and granular layer of the right cerebellar hemi-
sphere and vermis of elderly schizophrenic patients hos-
pitalized for the long term. These results point in the same
direction as increased expression of NR2D subunit in the
left prefrontal cortex [1]. Subtle shifts in composition of
NMDA receptors may have considerable effects on
receptor function. In contrast to receptors containing a
combination of NR1 with NR2A or NR2B subunits,
NMDA receptors assembled from NR1 and NR2D subunits
show a prolonged decay rate of glutamate-induced ion
currents and lowered threshold for voltage-dependent
magnesium blockade. This causes a ‘hyperexcitable’
receptor ensuring effective postsynaptic depolarization
when presynaptic activity is reduced [39]. Therefore, an
increased expression of NR2D subunit in schizophrenic
patients may be interpreted as a secondary regulation to
glutamatergic hypoactivity in the right cerebellum, which
was not seen in the left side. This supports results from the
left cerebellum revealing no alterations in schizophrenic
patients [1]. Additionally, we did not ﬁnd alterations of
NMDA receptor binding in our sample of schizophrenic
patients.
In patients suffering from schizophrenia, decreased
NMDA receptor function has been hypothesized to lead to
glutamatergic dysfunction in cortical projections [44]. The
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Fig. 3 Human: localization of rs35753505 (SNP8NRG221533) rel-
ative to NRG1 transcripts (RefSeq). Mouse and rat: localization of the
evolutionary conserved region (ECR) in red, in which the human SNP
is located. The orientation of the mouse sequence is reversed since
mouse Nrg1 is coded by the opposite strand. ECR coordinates refer to
the annotations of the ECR browser (hg18, February 2007) and of the
UCSC Genome Browser for mm9 and rn4 assemblies, respectively
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123schizophrenic phenotype may then appear in young adult-
hood, whenthe brain becomes vulnerableto the pre-existing
NMDA receptor hypofunction [19]. Genetic factors can
inﬂuence the brain and different risk genes associated with
schizophrenia are known to inﬂuence the glutamatergic
NMDA receptor such as dysbindin, metabotropic glutamate
receptor 3, prolindehydrogenase, G72, DAAO and NRG1
leading to an NMDA receptor hypofunction. Several studies
have identiﬁed the NRG1 gene as a candidate gene for
schizophrenia [23, 33]. The originally reported core at-risk
haplotype consists of two microsatellite markers and ﬁve
single nucleotide ploymorphosms (SNPs) [58]. The core
at-risk haplotype of seven markers can be identiﬁed
using only three markers (the SNP SNP8NRG221533
and the two microsatellites 478B14-848 and 420M9-1395)
[59]. As typing of the microsatellite markers results in
very small sample groups for each allelic type, we
focused on genotyping of the frequent SNP rs35753505
(SNP8NRG221533), which showed the best uncorrected
single marker association in the study of Stefansson et al.
[58] and is a commonly reported marker in schizophrenia
association studies [for metaanalysis/review see: 34, 40,
53, 59]. Positive association ﬁndings with rs35753505
(SNP8NRG221533) and schizophrenia or schizophrenia-
related phenotypes were reported: schizophrenia [57, 58,
62]; NRG1 SNP8NRG221533 and IL-1B -511 genotypes in
combination[20,22];nondeﬁcitschizophrenia[5];response
to conventional antipsychotics [31]; fractional anisotropy,
which reﬂects structural integrity of white matter [61]; P300
latency [9]; activation in brain regions important for
schizophrenia [32].
Thelocalizationofrs35753505(SNP8NRG221533)inan
ECR suggests selection and possible functional importance
of the DNA sequence which harbours this polymorphism.
Amongdistantlyrelated mammals,onlyafew percent ofthe
noncoding sequence is conserved, and within these regions
occurrence of functional variation has been suggested [15].
The code that underlies vertebrate gene regulation is still
not well understood [49]. Despite this uncertainty, evolu-
tionary sequence conservation is considered a reliable
indicator of biological activity [49], and several noncoding
ECRs were validated as enhancers [13, 38, 41, 49, 50].
Noncoding, intergenic or intronic, sequence identity
greater than or equal to 70% over at least 100 base pairs in
orthologous human–mouse alignments is a commonly used
threshold to detect ECRs [13–15, 37, 38, 41, 45, 49].
The localization of the ECR in which rs35753505
(SNP8NRG221533) is located, together with the position
upstream of the transcriptional start sites of all NRG1
transcript isoforms (RefSeq), as displayed in Fig. 3, sug-
gests that this chromosomal region may be of importance
for the transcriptional regulation of NRG1.
ECR :: Evolutionary 
Conserved Region 
Human[hg18] - Mouse[mm8] ECR
Type  400 bps, 74.8% identity 
Location chr8:31593526-31593925[hg18]
GC count 
Human .. GC: 31.75%, AT:68.25%, OTHER: 0.00%   
Mouse .. GC: 33.75%, AT: 66.25%, OTHER: 0.00%  
Alignment
ECR :: Evolutionary 
Conserved Region 
Human[hg18] - Rat[rn4] ECR
Type  295 bps, 73.6% identity 
Location chr8:31593526-31593820[hg18]
GC count 
Human .. GC: 31.19%, AT:68.81%, OTHER: 0.00%   
Rat .. GC: 33.22%, AT: 66.78%, OTHER: 0.00%  
Alignment
A
B
Fig. 4 ECR browser ‘Grab ECR’ alignment from both species in
pairwise comparisons (ECR browser, February 2007). a human/
mouse ECR, b human/rat ECR. Position of rs35753505
(SNP8NRG221533) is highlighted in grey. Additionally, the length,
percentage identity, G ? C content and genomic coordinates of the
ECR are given
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123The neuregulin-b isoform of NRG1 is known to induce
gene expression of the NR2C subunit in cerebellar neurons
[47], but is not the one in closest proximity to rs35753505
(SNP8NRG221533), rather suggesting an inﬂuence of the
polymorphism on the GGF2-isoform of NRG1. It was
proposed that neuregulin 1-coded signal molecules exert
inﬂuence on NMDA receptor subunit NR2C expression in
a transsynaptic mode: presynaptically located neuregulin
1-coded proteins are signal-dependent proteolytically
cleaved, the extracellular fragment released into the syn-
aptic cleft, where it binds to postsynaptic ErB receptors.
Activated ErB receptors then translocate to the nucleus and
inﬂuence postsynaptic NMDA receptor gene expression,
thus mediating the information from neuregulin 1-coded
proteins on the subunit composition of NMDA receptors in
the postsynaptic cell [46, 56]. Yet, the complete mecha-
nisms underlying the contribution of NRG1 risk genotypes
to disease pathophysiology remain elusive.
To the best of our knowledge, the impact of genetic
variation in NRG1 on the expression of NMDA receptor
subunits has not been studied so far. Our exploratory study
suggests that NRG1 may be involved in the regulation of
the expression of the NR2C subunit. In brain tissue with
genotypes containing at least one C allele of rs35753505
(SNP8NRG221533), NR2C expression was decreased.
This ﬁnding was conﬁned to the molecular layer of the
right cerebellum. Decreased expression may then lead to an
NMDA receptor hypofunction, since NR2C, as a major
NMDA receptor subunit of the cerebellum, exhibits less
marked voltage-sensitive magnesium blockade and pro-
longed decay rate of glutamate-induced ion currents [39].
A deﬁciency in this subunit may cause decreased receptor
activation during glutamatergic stimulation and, as a con-
sequence, diminished synaptic sprouting [36]. However,
we would like to point out that the results of our genetic
study should be viewed with caution, given that we pursued
an exploratory strategy, which did not include an adjust-
ment for multiple testing. Moreover, it is based on a limited
sample size. Thus, a replication of our ﬁnding in a larger
sample is warranted in order to evaluate the role of NRG1
polymorphism in the expression of NR2C subunits.
Beside its motor function, the cerebellum is activated
during attention [3]. Moreover, the cerebellum is lateral-
ized and, as shown in an fMRI study, the right cerebellum
and the left prefrontal cortex are both activated during a
silent ﬂuency task in right-handed healthy subjects [24]. It
has been proposed that a cortical-thalamic-cerebellar-cor-
tical circuit may be disturbed in the pathophysiology of
schizophrenia and may lead to a misconnection syndrome
with consecutive impairments of cognitive processes [4].
Cognitive functioning depends on the plasticity mediated,
in part, by NMDA receptors [11]. Consistent with
this,
1H-MRS as well as gene expression studies in
schizophrenia reveal a hypoglutamatergic deﬁcit in the left
prefrontal cortex [1, 6], thalamus [25, 55] and cerebellum
[16]. In the granule cell layer of the cerebellar cortex, the
glutamatergic synaptic protein complexin II was reduced at
the mRNA and protein level in schizophrenia patients
compared to healthy controls [16]. However, these authors
did not distinguish between the left and right hemisphere.
Inline with this study, our results suggest a hypoglutama-
tergic deﬁcit in schizophrenia. In this respect, our study is
the ﬁrst to describe lateralized alterations on the molecular
level.
Since all patients involved in this study had been treated
with antipsychotics over decades, medication effects may
have inﬂuenced our results. In both sides of the cerebellum,
expression of the NR2C subunit correlated with the dura-
tion of medication and our animal study revealed increased
expression in clozapine-treated rats compared to haloperi-
dol treatment. Therefore, clozapine may be superior to
haloperidol in restoring a deﬁcit of NR2C expression in the
right cerebellum. However, it must also be noted that the
study showed no differences between saline-treated rats
and treatment groups. Additionally, duration of medication
seemed to inﬂuence expression of the NR2D subunit only
in the left cerebellum where we did not detect differences
between patients and normal comparison subjects. In
contrast, duration of illness may have an inﬂuence on
NR2C and NR2D expression, but again, on the right side,
where we only found diagnostic effects for NR2D
expression, and observed no signiﬁcant correlations with
duration of illness.
A limiting factor of our study is its small sample and the
ensuing fact that results will become insigniﬁcant after
corrections for multiple testing. Thus, the results of this
explorative study should be veriﬁed in a larger sample.
Since many ﬁndings in post-mortem tissue are not speciﬁc
for schizophrenia, psychiatric patients with other diagnoses
such as bipolar disorder should be investigated to show
disease-speciﬁc effects on NMDA receptor expression.
Moreover, since we did not investigate protein levels of
NMDA receptor subunits, it is not clear, if changes in the
level of the mRNA transcript also reﬂect changes in protein
levels, again limiting our conclusions. A complex interac-
tion of genes, such as NRG1 (or other promising vulnera-
bility genes) and environmental factors may contribute to
the aetiology of schizophrenia. Although the results of our
study point to alterations in gene expression of NMDA
receptor subunits, further studies are warranted to elucidate
the precise nature of the glutamatergic hypofunction in
schizophrenia.
Acknowledgments This study was supported by the European
Commission under the Sixth Framework Programme (BrainNet Eur-
ope II, LSHM-CT-2004-503039). The paper reﬂects only the authors’
Eur Arch Psychiatry Clin Neurosci (2010) 260:101–111 109
123views and the Community is not liable for any use that may be made
of it. The authors would like to thank Udo Rueb for Braak staging and
Mrs. Waltraud VanSyckel for English text revision.
Conﬂict of interest statement All authors (Andrea Schmitt, Jiri
Koschel,MathiasZink,ManfredBauer,ClemensSommer,JosefFrank,
Jens Treutlein, Thomas Schulze, Thomas Schneider-Axmann, Eleni
Parlapani, Marcella Rietschel, Peter Falkai, Fritz A Henn) reported no
biomedical ﬁnancial interests or potential conﬂicts of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick
WP, Potkin SG, Sandman CA, Bunney WE Jr, Jones EG (1996)
Selective alterations in gene expression for NMDA receptor sub-
units in prefrontal cortex of schizophrenics. J Neurosci 16:19–30
2. Akshoomoff NA, Courchesne E, Townsend J (1997) Attention
coordination and anticipatory control. Int Rev Neurobiol 41:575–
598
3. Allen G, Buxton RB, Wong EC, Courchesne E (1997) Attentional
activation of the cerebellum independent of motor involvement.
Science 275:1940–1943
4. Andreasen NC, Nopoulos P, O’Leary DS, Miller DD, Wassink T,
Flaum M (1999) Deﬁning the phenotype of schizophrenia: cog-
nitive dysmetria and its neural mechanisms. Biol Psychiatry
46:908–920
5. Bakker SC, Hoogendoorn ML, Selten JP, Verduijn W, Pearson
PL, Sinke RJ, Kahn RS (2004) Neuregulin 1: genetic support for
schizophrenia subtypes. Mol Psychiatry 9:1061–1063
6. Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L,
Canaran G, Rylett RJ, Neufeld RWJ (1997) Measurement of
glutamate and glutamine in the medial prefrontal cortex of never-
treated schizophrenic patients and healthy controls by proton
magnetic resonance spectroscopy. Arch Gen Psychiatry 54:959–
965
7. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K
(2006) Staging of Alzheimer disease-associated neuroﬁbrillary
pathology using parafﬁn sections and immunocytochemistry.
Acta Neuropathol 112:389–404
8. Braak H, Braak E (1991) Neuropathological stageing of Alzhei-
mer-related changes. Acta Neuropathol 82:239–259
9. Bramon E, Dempster E, Frangou S, Shaikh M, Walshe M, Filbey
FM, McDonald C, Sham P, Collier DA, Murray R (2008) Neu-
regulin-1 and the P300 waveform—a preliminary association
study using a psychosis endophenotype. Schizophr Res 103:178–
185
10. Cull-Candy SG, Brickley SG, Misra C, Feldmeyer D, Momiyama
A, Farrant M (1998) NMDA receptor diversity in the cerebellum:
identiﬁcation of subunits contributing to functional receptors.
Neuropharmacology 37:1369–1380
11. Daw NW, Stein PS, Fox K (1993) The role of NMDA receptors
in information processing. Annu Rev Neurosci 16:207–222
12. Deicken RF, Feiwell R, Schuff N, Soher B (2001) Evidence for
altered cerebellar vermis neuronal integrity in schizophrenia.
Psychiatry Res 107:125–134
13. Dermitzakis ET, Reymond A, Antonarakis SE (2005) Conserved
non-genic sequences—an unexpected feature of mammalian
genomes. Nat Rev Genet 6:151–157
14. DeSilva U, Elnitski L, Idol JR, Doyle JL, Gan W, Thomas JW,
Schwartz S, Dietrich NL, Beckstrom-Sternberg SM, McDowell
JC et al (2002) Generation and comparative analysis of approx-
imately 3.3 Mb of mouse genomic sequence orthologous to the
region of human chromosome 7q11.23 implicated in Williams
syndrome. Genome Res 12:3–15
15. Drake JA, Bird C, Nemesh J, Thomas DJ, Newton-Cheh C,
Reymond A, Excofﬁer L, Attar H, Antonarakis SE, Dermitzakis
ET, Hirschhorn JN (2006) Conserved noncoding sequences are
selectively constrained and not mutation cold spots. Nat Genet
38:223–227
16. Eastwood SL, Cotter D, Harrison PJ (2001) Cerebellar synaptic
protein expression in schizophrenia. Neuroscience 105:219–229
17. Ende G, Hubrich P, Walter S, Weber-Fahr W, Ka ¨mmerer N,
Braus DF, Henn FA (2005) Further evidence for altered cere-
bellar neuronal integrity in schizophrenia. Am J Psychiatry
162:790–792
18. Farber NB, Newcomer JW, Olney JW (1999) Glycine agonists:
what can they teach us about schizophrenia? Arch Gen Psychiatry
56:13–17
19. Farber NB, Wozniak DF, Price MT, Labruyere J, Huss J, St Peter
H, Olney JW (1995) Age-speciﬁc neurotoxicity in the rat asso-
ciated with NMDA receptor blockade: potential relevance to
schizophrenia? Biol Psychiatry 38:788–796
20. Georgieva L, Dimitrova A, Ivanov D, Nikolov I, Williams NM,
Grozeva D, Zaharieva I, Toncheva D, Owen MJ, Kirov G,
O’Donovan MC (2008) Support for neuregulin 1 as a suscepti-
bility gene for bipolar disorder and schizophrenia. Biol Psychi-
atry 64:419–427
21. Ghez C, Fahn S (1985) The cerebellum. In: Kandel ER, Schwartz
JH (eds) Principals of neural science. Elsevier, New York, pp
502–522
22. Ha ¨nninen K, Katila H, Saarela M, Rontu R, Mattila KM, Fan M,
Hurme M, Lehtima ¨ki T (2008) Interleukin-1 beta gene poly-
morphism and its interactions with neuregulin-1 gene polymor-
phism are associated with schizophrenia. Eur Arch Psychiatry
Clin Neurosci 258:10–15
23. Harrison PJ, Weinberger DR (2005) Schizophrenia genes, gene
expression, and neuropathology: on the matter of their conver-
gence. Mol Psychiatry 10:40–68
24. Hubrich-Ungureanu P, Kaemmerer N, Henn FA, Braus DF
(2002) Lateralized organization of the cerebellum in a silent
verbal ﬂuency task: a functional magnetic resonance imaging
study in healthy volunteers. Neurosci Lett 319:91–94
25. Ibrahim HM, Hogg AJ Jr, Healy DJ, Haroutunian V, Davis KL,
Meador-Woodruff JH (2000) Ionotropic glutamate receptor
binding and subunit mRNA expression in thalamic nuclei in
schizophrenia. Am J Psychiatry 157:1811–1823
26. Ichimiya T, Okubo Y, Suhara T, Sudo Y (2001) Reduced volume
of the cerebellar vermis in neuroleptic-naive schizophrenia. Biol
Psychiatry 49:20–27
27. Ishii T, Moriyoshi K, Sugihara H, Sakurada K, Kadotani H,
Yokoi M, Akazawa C, Shigemoto R, Mizuno N, Masu M et al
(1993) Molecular characterization of the family of the
N-methyl-D-aspartate receptor subunits. J Biol Chem 268:2836–
2843
28. Jahn T, Mussgay L (1989) Die statistische Kontrolle mo ¨glicher
Medikamenteneinﬂu ¨sse in experimentalpsychologischen Schizo-
phreniestudien: ein Vorschlag zur Berechnung von Chlorproma-
zina ¨quivalenten. Z Klin Psychol 18:257–267
29. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine
model of schizophrenia. Am J Psychiatry 148:1301–1308
30. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of
phencyclidine: from NMDA receptor hypofunction to the dopa-
mine hypothesis of schizophrenia. Neuropsychopharmacology
20:201–225
110 Eur Arch Psychiatry Clin Neurosci (2010) 260:101–111
12331. Kampman O, Anttila S, Illi A, Saarela M, Rontu R, Mattila KM,
Leinonen E, Lehtima ¨ki T (2004) Neuregulin genotype and
medication response in Finnish patients with schizophrenia.
NeuroReport 15:2517–2520
32. Kircher T, Thienel R, Wagner M, Reske M, Habel U, Kellermann
T, Frommann I, Schwab S, Wo ¨lwer W, von Wilmsdorf M et al
(2009) Neuregulin 1 ICE-single nucleotide polymorphism in ﬁrst
episode schizophrenia correlates with cerebral activation in
fronto-temporal areas. Eur Arch Psychiatry Clin Neurosci
259:72–79
33. Law AJ, Lipska BK, Weickert CS, Hyde TM, Straub RE,
Hashimoto R, Harrison PJ, Kleinman JE, Weinberger DR (2006)
Neuregulin 1 transcripts are differentially expressed in schizo-
phrenia and regulated by 50 SNPs associated with the disease.
Proc Natl Acad Sci USA 103:6747–6752
34. Li D, Collier DA, He L (2006) Meta-analysis shows strong
positive association of the neuregulin 1 (NRG1) gene with
schizophrenia. Hum Mol Genet 15:1995–2002
35. Lillifors H (1967) On the Kolmogorov–Smirnov test for nor-
mality with mean and variance unknown. J Am Stat Assoc 62:399
36. Lipton SA, Kater SB (1989) Neurotransmitter regulation of
neuronal outgrowth, plasticity and survival. Trends Neurosci
12:265–270
37. Liu J, Francke U (2006) Identiﬁcation of cis-regulatory elements
for MECP2 expression. Hum Mol Genet 15:1769–1782
38. Loots GG, Locksley RM, Blankespoor CM, Wang ZE, Miller W,
Rubin EM, Frazer KA (2000) Identiﬁcation of a coordinate reg-
ulator of interleukins 4, 13, and 5 by cross-species sequence
comparisons. Science 288:136–140
39. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH
(1994) Developmental and regional expression in the rat brain
and functional properties of four NMDA receptors. Neuron
12:529–540
40. Munafo MR, Thiselton DL, Clark TG, Flint J (2006) Association
of the NRG1 gene and schizophrenia: a meta-analysis. Mol
Psychiatry 11:539–546
41. Nobrega MA, Ovcharenko I, Afzal V, Rubin EM (2003) Scan-
ning human gene deserts for long-range enhancers. Science
302:413
42. Norusis M (2000) SPSS
 10.0 Guide to data analysis. Prentice
Hall, Upper Saddle River, New Jersey
43. Okugawa G, Sedvall G, Nordstro ¨m M, Andreasen N, Pierson R,
Magnotta V, Agartz I (2002) Selective reduction of the posterior
superior vermis in men with chronic schizophrenia. Schizophr
Res 55:61–67
44. Olney JW, Farber NB (1995) Glutamate receptor dysfunction and
schizophrenia. Arch Gen Psychiatry 52:998–1007
45. Ovcharenko I, Nobrega MA, Loots GG, Stubbs L (2004) ECR
Browser: a tool for visualizing and accessing data from com-
parisons of multiple vertebrate genomes. Nucleic Acids Res
32:W280–W286
46. Ozaki M, Tohyama K, Kishida H, Buonanno A, Yano R, Has-
hikawa T (2000) Roles of neuregulin in synaptogenesis between
mossy ﬁbers and cerebellar granule cells. J Neurosci Res 59:612–
623
47. Ozaki M, Sasner M, Yano R, Lu HS, Buonanno A (1997)
Neuregulin-beta induces expression of an NMDA-receptor sub-
unit. Nature 390:691–694
48. Paxinos G, Watson C (1986) The rat brain in sterotaxic coordi-
nates. Academic Press, Marrickville
49. Pennacchio LA, Loots GG, Nobrega MA, Ovcharenko I (2007)
Predicting tissue-speciﬁc enhancers in the human genome. Gen-
ome Res 17:201–211
50. Pennacchio LA, Ahituv N, Moses AM, Prabhakar S, Nobrega
MA, Shoukry M, Minovitsky S, Dubchak I, Holt A, Lewis KD
et al (2006) In vivo enhancer analysis of human conserved non-
coding sequences. Nature 444:499–502
51. Rees G, Frackowiak R, Frith C (1997) Two modulatory effects of
attention that mediate object categorization in human cortex.
Science 275:835–838
52. Scherzer CR, Landwehrmeyer GB, Kerner JA, Standaert DG,
Hollingsworth ZR, Daggett LP, Velicelebi G, Penney JB Jr,
Young AB (1997) Cellular distribution of NMDA glutamate
receptor subunit mRNAs in the human cerebellum. Neurobiol Dis
4:35–46
53. Schmitt A, Parlapani E, Gruber O, Wobrock T, Falkai P (2008)
Impact of neuregulin-1 on the pathophysiology of schizophrenia
in human post-mortem studies. Eur Arch Psychiatry Clin Neu-
rosci 258(Suppl 5):35–39
54. Schmitt A, Zink M, Mu ¨ller B, May B, Herb A, Jatzko A, Braus
DF, Henn FA (2003) Effects of long-term antipsychotic treatment
on NMDA receptor binding and gene expression of subunits.
Neurochem Res 28:235–241
55. Smith RE, Haroutunian V, Davis KL, Meador-Woodruff JH
(2001) Expression of excitatory amino acid transporter transcripts
in the thalamus of subjects with schizophrenia. Am J Psychiatry
158:1393–1399
56. Stefansson H, Steinthorsdottir V, Thorgeirsson TE, Gulcher JR,
Stefansson K (2004) Neuregulin 1 and schizophrenia. Ann Med
36:62–71
57. Stefansson H, Sarginson J, Kong A, Yates P, Steinthorsdottir V,
Gudﬁnnsson E, Gunnarsdottir S, Walker N, Petursson H, Crom-
bie C et al (2003) Association of neuregulin 1 with schizophrenia
conﬁrmed in a Scottish population. Am J Hum Genet 72:83–87
58. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S,
Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S,
Ivarsson O, Chou TT et al (2002) Neuregulin 1 and susceptibility
to schizophrenia. Am J Hum Genet 71:877–892
59. Tosato S, Dazzan P, Collier D (2005) Association between the
neuregulin 1 gene and schizophrenia: a systematic review.
Schizophr Bull 31:613–617
60. Volz H, Gaser C, Sauer H (2000) Supporting evidence for the
model of cognitive dysmetria in schizophrenia—a structural
magnetic resonance imaging study using deformation-based
morphometry. Schizophr Res 46:45–56
61. Winterer G, Konrad A, Vucurevic G, Musso F, Stoeter P, Dah-
men N (2008) Association of 50 end neuregulin-1 (NRG1) gene
variation with subcortical medial frontal microstructure in
humans. Neuroimage 40:712–718
62. Yang JZ, Si TM, Ruan Y, Ling YS, Han YH, Wang XL, Zhou M,
Zhang HY, Kong QM, Liu C et al (2003) Association study of
neuregulin 1 gene with schizophrenia. Mol Psychiatry 8:706–709
63. Zilles K, Qu ¨ MS, Ko ¨hling R, Speckmann EJ (1999) Ionotropic
glutamate and GABA receptors in human epileptic neocortical
tissue: quantitative in vitro receptor autoradiography. Neurosci-
ence 94:1051–1061
64. Zink M, Schmitt A, May B, Mu ¨ller B, Demirakca T, Braus DF,
Henn FA (2004) Differential effects of long-term treatment with
clozapine or haloperidol on GABAA receptor binding and
GAD67 expression. Schizophr Res 66:151–157
Eur Arch Psychiatry Clin Neurosci (2010) 260:101–111 111
123